摘要
目的系统评价头孢他啶阿维巴坦(ceftazidime/avibactam,CAZ/AVI)单药治疗与联合治疗碳青霉烯耐药肠杆菌(carbapenem resistant enterobacteriaceae,CRE)感染的有效性和安全性。方法计算机检索CNKI、Wanfang Data、CBM、PubMed、The Cochrane Library、Web of Science、Embase,检索时间为建库至2021年4月,查找CAZ/AVI单药治疗与联合治疗CRE感染的研究。对符合纳入条件的研究进行资料提取和质量评价后,采用RevMan 5.3统计软件进行meta分析。结果共纳入13项研究,合计1452例患者。Meta分析结果显示,CAZ/AVI单药治疗对比联合治疗CRE的病死率[RR=0.98,95%CI(0.82,1.17),P=0.82]、微生物清除率[RR=1.02,95%CI(0.8,1.28),P=0.89]、临床治愈率[RR=0.97,95%CI(0.83,1.13),P=0.66]差异无统计学意义。结论基于目前的研究结果,CAZ/AVI单药治疗与联合治疗CRE的疗效与安全性无显著差异,该结果尚需更多前瞻性研究以及随机对照研究的验证。
OBJECTIVE To evaluate the efficacy and safety of ceftazidime/avibactam(CAZ/AVI)in monotherapy or combination therapy against carbapenem resistant enterobacteriaceae(CRE)infection.METHODS CNKI,Wanfang Data,CBM,PubMed,The Cochrane Library,Web of Science and Embase were searched by computer from construction to April 2021.To investigate the study of CAZ/AVI monotherapy and combination therapy for CRE infection.After data extraction and quality assessment of the eligible studies,RevMan 5.3 statistical software was used for meta-analysis.RESULTS A total of 13 studies involving 1452 patients were included.The results of meta-analysis showed that compared with the combined treatment of CAZ/AVI,the mortality rate[RR=0.98,95%CI(0.82,1.17),P=0.82],microbial clearance rate[RR=1.02,95%CI(0.8,1.28),P=0.89]and the clinical cure rate[RR=0.97,95%CI(0.83,1.13),P=0.66]of monotherapy had no statistically significant.CONCLUSION Based on the current study results,there is no significant difference in the efficacy and safety of CAZ/AVI monotherapy and combination therapy for CRE,which needs to be verified by more prospective studies and randomized controlled studies.
作者
崔志红
林雪芳
姚根琴
CUI Zhihong;LIN Xuefang;YAO Genqin(Traditional Chinese Medicine Hospital of Changxing,Huzhou 313100,China)
出处
《中国现代应用药学》
CAS
CSCD
北大核心
2022年第11期1470-1477,共8页
Chinese Journal of Modern Applied Pharmacy
基金
浙江省医学会临床科研基金项目(2021ZYC-B13)